ペグセタコプランの長期安全性および有効性延長試験
発作性夜間ヘモグロビン尿症(PNH)の治療におけるペグセタコプランの長期的な安全性と有効性を評価するための非盲検、非無作為化、多施設延長試験
This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90033
- University of Southern California
-
-
Colorado
-
Denver、Colorado、アメリカ、80204
- Denver Health Medical Center
-
-
Florida
-
Jacksonville、Florida、アメリカ、32257
- Cancer Specialists of North Florida
-
Miami、Florida、アメリカ、33014
- Lakes Research
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46260
- Investigative Clinical Research of Indiana
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- Duke University Medical Center
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38120
- Baptist Cancer Center
-
-
-
-
-
Leeds、イギリス、LS9 7TF
- Leeds Teaching Hospitals NHS Trust
-
-
-
-
Victoria
-
Melbourne、Victoria、オーストラリア、3000
- Royal Melbourne Hospital
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N 4Z6
- University of Calgary
-
Edmonton、Alberta、カナダ、T6G 2V2
- Alberta Health Services
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 2C4
- Toronto General Hospital
-
-
-
-
Valle del Cauca Department
-
Cali、Valle del Cauca Department、コロンビア、760035
- IPS Centro Medico Julian Coronel SAS
-
-
-
-
-
Singapore、シンガポール、169608
- Singapore General Hospital
-
-
-
-
-
Valencia、スペイン、46026
- Hospital Universitario Politecnico La Fe
-
-
Canary Islands
-
Las Palmas de Gran Canaria、Canary Islands、スペイン、35019
- Hospital Univ. de Gran Canaria Dr.Negrin
-
-
-
-
-
Belgrade、セルビア、11000
- Clinical Center of Serbia
-
-
-
-
-
Bangkok、タイ、10400
- Phramongkutklao Hospital
-
Bangkok、タイ、10400
- Ramathibodi Hospital
-
Bangkok、タイ、10400
- Siriraj Hospital
-
Chiang Mai、タイ、50200
- Maharaj Nakorn Chiang Mai Hospital
-
Khon Kaen、タイ、40002
- Srinagarind Hospital
-
Pathum Thani、タイ、12120
- Thammasat University Hospital
-
Songkhla、タイ、90110
- Songklanagarind Hospital
-
-
-
-
-
Hamburg、ドイツ、20246
- University Medical Center Hamburg-Eppendorf
-
-
Baden-Wurttemberg
-
Ulm、Baden-Wurttemberg、ドイツ、89081
- Universitatsklinikum Ulm
-
-
North Rhine-Westphalia
-
Aachen、North Rhine-Westphalia、ドイツ、52074
- Uniklinik RWTH Aachen
-
Essen、North Rhine-Westphalia、ドイツ、45147
- Essen University Hospital Department of Hematology
-
-
-
-
National Capital Region
-
Cebu、National Capital Region、フィリピン、6000
- Perpetual Succour Hospital
-
Lipa City、National Capital Region、フィリピン、4217
- Mary Mediatrix Medical Centre
-
Makati City、National Capital Region、フィリピン、1229
- Makati Medical Centre
-
Pasig、National Capital Region、フィリピン、1604
- The Medical City
-
Quezon City、National Capital Region、フィリピン、1112
- St. Lukes Medical Centre
-
-
-
-
-
Chalon-sur-Saône、フランス、71100
- Hospital Center Chalon Sur Saone William Morey
-
Lille、フランス、59037
- CHRU de Lille
-
Paris、フランス、75010
- Hopital Saint-Louis
-
Pierre-Bénite、フランス、69495
- Lyon Sud Hospital Center
-
Pringy、フランス、74374
- Centre Hospitalier Annecy Genevois - Site Annecy
-
Saint-Quentin、フランス、02321
- Centre Hospitalier de Saint-Quentin
-
-
-
-
-
Sofia、ブルガリア、1407
- Acibadem City Clinic Tokuda Hospital
-
Sofia、ブルガリア、1756
- National Specialized Hospital for Active Treatment of Haematologic Diseases
-
-
-
-
-
Brussels、ベルギー、1200
- Cliniques Universitaires Saint-luc
-
Roeselare、ベルギー、8800
- AZ Delta
-
-
-
-
Lima
-
Jesús María、Lima、ペルー、15072
- Hospital Edgardo Rebagliatti
-
-
Lima region
-
Lima Cercado、Lima region、ペルー、15003
- Hospital Nacional Dos De Mayo - Centro de Investigación
-
San Isidro、Lima region、ペルー、15047
- Centro de Investigacion en Hematologia Clinica del Centro Medico Corpac
-
-
-
-
Kuala Lumpur
-
Lembah Pantai、Kuala Lumpur、マレーシア、59100
- University Malaya Medical Centre
-
-
Selangor
-
Ampang、Selangor、マレーシア、68000
- Hospital Ampang
-
-
-
-
-
Monterrey、メキシコ、64460
- Hospital Universitario "José Eleuterio González", UANL
-
-
-
-
-
Saint Petersburg、ロシア、197022
- Pavlov First Saint Petersburg State Medical University
-
Tyumen、ロシア、625023
- Therapeutic hospital of regional clinical hospital #1
-
-
-
-
-
Okayama、日本、700-8558
- Okayama University Hospital
-
Tokyo、日本、141-0022
- NTT Medical Center Tokyo
-
-
Aichi-ken
-
Showa-ku、Aichi-ken、日本、486-8650
- Japanese Red Cross Nagoya Daini Hospital
-
-
Nagano
-
Matsumoto、Nagano、日本、390-8621
- Shinshu University Hospital
-
-
Tokyo
-
Bunkyō-Ku、Tokyo、日本、113-8421
- Juntendo University Hospital
-
-
Wakayama
-
Tanabe、Wakayama、日本、646-8588
- Kinan Hospital
-
-
-
-
Daejeon
-
Junggu、Daejeon、韓国、35015
- Chungnam National University Hospital
-
-
-
-
-
Hong Kong、香港
- Queen Mary Hospital
-
Hong Kong、香港
- Prince of Wales Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
-
Subjects at least 18 years of age with PNH who have participated in a pegcetacoplan clinical trial. Subjects who received treatment with pegcetacoplan must have experienced clinical benefit and adequate tolerability in the opinion of the investigator.
Note: Subjects with PNH who completed a pegcetacoplan clinical trial without receiving pegcetacoplan (or without receiving pegcetacoplan for long enough to demonstrate clinical benefit) may be enrolled in this study if, in the opinion of the Investigator, the subject is expected to demonstrate clinical benefit upon the initiation or continuation of pegcetacoplan therapy.
-
Vaccination against Neisseria meningitidis types A, C, W, Y and B, Streptococcus pneumoniae and Haemophilus influenzae Type B (Hib) either within 2 years prior to Day 1 dosing of this study, or within 14 days after starting treatment with pegcetacoplan. Vaccination is mandatory unless documented evidence exists that subjects are nonresponders to vaccination as evidenced by titers or display titer levels within acceptable local limits. Immunization status checks will be performed to determine whether subjects require primary or booster vaccinations.
-
Willing and able to give written informed consent.
-
Willing and able to self-administer pegcetacoplan (administration by caregiver will be allowed)
-
Women of childbearing potential (WOCBP) defined as any females who have experienced menarche and who are NOT permanently sterile or postmenopausal must have a negative pregnancy test and must agree to continue to use an approved method of contraception for the duration of the study and 90 days after their last dose of study drug. Note: Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.
-
Males must agree to continue to use an approved method of contraception and must agree to refrain from donating sperm for the duration of the study and 90 days after their last dose of study drug.
Exclusion Criteria:
- Subjects who have withdrawn from a pegcetacoplan clinical study.
- Any condition that could increase the subject's risk by participating in the study.
- Any comorbidity or condition (such as malignancy) that, in the opinion of the investigator, could put the subject at increased risk or potentially confound study data.
- History or presence of hypersensitivity or idiosyncratic reaction to compounds related to the investigational product or SC administration.
- Known infection with hepatitis B, C, or HIV.
- Hereditary complement deficiency.
- History of bone marrow transplant.
- Concurrent severe aplastic anemia (SAA), defined as currently receiving immunosuppressive therapy for SAA including but not limited to cyclosporin A, tacrolimus, mycophenolate mofetil or anti-thymocyte globulin.
- History of meningococcal disease.
- Concomitant treatment with any complement inhibitor (eg, eculizumab, ravulizumab).
- Pregnancy, breastfeeding, or positive pregnancy test.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:1,080 mg pegcetacoplan administered subcutaneously
1,080mg pegcetacoplan administered subcutaneously twice weekly or every three days. |
Complement (C3) Inhibitor |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
時間枠:From first dose of study drug up to 8 weeks from last dose (up to approximately 4 years or until pegcetacoplan development in participants with PNH was terminated)
|
An adverse event (AE) is any untoward medical occurrence associated with use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign, including a clinically significant abnormal laboratory finding, symptom, or disease temporally associated with the use of a study drug, whether or not considered related to the study drug. TEAEs were defined as those AEs that occurred or worsened in severity after the first dose of pegcetacoplan. |
From first dose of study drug up to 8 weeks from last dose (up to approximately 4 years or until pegcetacoplan development in participants with PNH was terminated)
|
|
Number of Participants With Thromboembolic Events
時間枠:From first dose of study drug up to 8 weeks from last dose (up to approximately 4 years or until pegcetacoplan development in participants with PNH was terminated)
|
From first dose of study drug up to 8 weeks from last dose (up to approximately 4 years or until pegcetacoplan development in participants with PNH was terminated)
|
|
|
Change From Baseline in Hematology Parameters (Erythrocytes)
時間枠:Baseline, Weeks 168 and 264
|
Baseline, Weeks 168 and 264
|
|
|
Change From Baseline in Hematology Parameters (Leukocytes, Platelets and Reticulocytes)
時間枠:Baseline, Weeks 168 and 264
|
Baseline, Weeks 168 and 264
|
|
|
Change From Baseline in Hematology Parameters (Hematocrit)
時間枠:Baseline, Weeks 168 and 264
|
Baseline, Weeks 168 and 264
|
|
|
Change From Baseline in Hematology Parameters (Hemoglobin)
時間枠:Baseline, Weeks 168 and 264
|
Baseline, Weeks 168 and 264
|
|
|
Change From Baseline in Serum Chemistry Parameters [Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Lactate Dehydrogenase (LDH)]
時間枠:Baseline, Weeks 168 and 264
|
Baseline, Weeks 168 and 264
|
|
|
Change From Baseline in Serum Chemistry Parameters (Bilirubin)
時間枠:Baseline, Weeks 168 and 264
|
Baseline, Weeks 168 and 264
|
|
|
Number of Participants With Post-Baseline Potentially Clinically Significant Abnormal Coagulation Parameters
時間枠:Baseline, Week 264
|
Coagulation parameters included Activated Partial Thromboplastin Time (APTT), D-Dimer, Fibrinogen, Prothrombin Intl. Normalized Ratio and Prothrombin Time. |
Baseline, Week 264
|
|
Number of Participants With Post-Baseline Potentially Clinically Significant Abnormal Urinalysis Parameters
時間枠:Baseline, Week 264
|
Urinalysis parameters included ketones, leukocyte esterase, nitrite, occult blood, pH, protein, specific gravity and urobilinogen. |
Baseline, Week 264
|
|
Number of Participants With Shift From Baseline in Clinically Significant Abnormalities in Electrocardiograms (ECG)
時間枠:Baseline, Week 324
|
ECG measurements included heart rate, PR, QT, QRS, QTcB and QTcF. |
Baseline, Week 324
|
|
Change From Baseline in Hemoglobin Concentration
時間枠:Baseline, Week 324
|
Baseline, Week 324
|
|
|
Change From Baseline in Lactate Dehydrogenase (LDH) Concentration
時間枠:Baseline, Week 324
|
Baseline, Week 324
|
|
|
Change From Baseline in Indirect Bilirubin Level
時間枠:Baseline, Week 324
|
Baseline, Week 324
|
|
|
Change From Baseline in Absolute Reticulocyte Count (ARC)
時間枠:Baseline, Week 324
|
Baseline, Week 324
|
|
|
Number of Participants Who Received Packed Red Blood Cell Transfusions (PRBCs)
時間枠:From first dose of study drug up to 8 weeks from last dose (up to approximately 4 years or until pegcetacoplan development in participants with PNH was terminated)
|
Transfusion included whole blood, PRBCs, leukocyte-depleted red blood cells (LDPRCs), and all types of red blood cell (RBC) transfusions. |
From first dose of study drug up to 8 weeks from last dose (up to approximately 4 years or until pegcetacoplan development in participants with PNH was terminated)
|
|
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score
時間枠:Baseline, Week 324
|
The FACIT-Fatigue scale consists of 13 questions that assess fatigue and its impact on daily activities over the past 7 days. Each question is scored on a 5-point scale from 0 ("not at all") to 4 ("very much"). For items where a higher response indicates greater fatigue, the score is reversed so that all items are scored in the same direction. The scores from the 13 items are then added together to calculate the FACIT-Fatigue total score. The total score ranges from 0 to 52, with higher scores indicating less fatigue and better functioning. |
Baseline, Week 324
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- de Castro C, Kelly RJ, Griffin M, Patriquin CJ, Mulherin B, Hochsmann B, Selvaratnam V, Wong RSM, Hillmen P, Horneff R, Uchendu UO, Zhang Y, Surova E, Szamosi J, de Latour RP. Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan. Adv Ther. 2025 Sep;42(9):4641-4658. doi: 10.1007/s12325-025-03310-8. Epub 2025 Jul 28.
- Patriquin CJ, Bogdanovic A, Griffin M, Kelly RJ, Maciejewski JP, Mulherin B, Peffault de Latour R, Roth A, Selvaratnam V, Szer J, Al-Adhami M, Horneff R, Tan L, Yeh M, Panse J. Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study. Adv Ther. 2024 May;41(5):2050-2069. doi: 10.1007/s12325-024-02827-8. Epub 2024 Apr 4.
- Griffin M, Kelly RJ, Panse J, de Castro C, Szer J, Horneff R, Tan L, Yeh M, Peffault de Latour R. Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH. Blood Adv. 2024 Apr 9;8(7):1776-1786. doi: 10.1182/bloodadvances.2023011691.
- Sharma V, Koprivnikar J, Drago K, Savage J, Bachelor A. Injection Site Reactions with Long-Term Pegcetacoplan Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Brief Report. Adv Ther. 2023 Nov;40(11):5115-5129. doi: 10.1007/s12325-023-02653-4. Epub 2023 Sep 14.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- APL2-307
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。